Guggenheim trimmed its price target (PT) on Amgen (NASDAQ:AMGN) to $340 from $351 on Monday, May 4, while maintaining a ...

Amgen’s first quarter results reflected the company’s ability to outpace the impact of ongoing patent expirations and ...

Viridian Therapeutics unveiled solid results Tuesday for its experimental eye disease treatment, a potential rival to Amgen.

Thousand Oaks-based Amgen continues to invest in its onshore capabilities, after the biotech giant announced plans to invest an additional $300 million in its U.S. manufacturing network to further ...

The FDA has renewed calls for Amgen’s Tavneos to be pulled from the market, saying it has discovered new evidence that study ...

May 4 () - Amgen said on Monday it was investing an additional $300 ‌million in Puerto Rico to expand ‌its U. Global ...

LOS ANGELES (Reuters) -Amgen on Monday launched direct-to-consumer U.S. sales of its cholesterol-lowering medication Repatha at a discounted cash price, becoming the latest pharmaceutical company to ...

Dr. Howard Chang, fourth from left, Amgen's senior vice president global research & chief scientific officer, with fellows in the biotech company's new postbaccalaureate fellowship program. The ...

Repatha’s withdrawal from Denmark is best understood as an early signal of the impact of Most Favored Nation drug pricing ...

Thousand Oaks pharma giant Amgen Inc. is making a series of C-suite changes, triggered by the retirement announcement of ...

Baron Capital, an investment management company, released its Q1 2026 investor letter for the “Baron Health Care Fund”. A ...

Amgen has pulled the plug on midstage drug candidates for cancer and the autoimmune disease Sjögren’s syndrome, terminating ...